+91 80 2808 2808

Update on Company Statement on US-FDA Inspection at Biocon Malaysia

  • Posted by: BIOCON

13th March, 2018

“Biocon had issued a statement to the stock exchanges on Feb 21, 2018, that the US-FDA completed a pre-approval inspection of its manufacturing facility in Malaysia and issued a Form 483 with 6 observations. As per the normal process, the Company has already submitted the Corrective and Preventive Action Plan (CAPA) to address these observations to the regulator” – Biocon Spokesperson.

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>